7Suppliers
4Customers
3Debt Items
20Related Chains

Jaguar Health, Inc. Suppliers

TickerNameConfidenceEvidence
UPTOWN-CAPITAL-LLC UPTOWN-CAPITAL-LLC 92% the Company issued 500 shares of Series Q Perpetual Preferred Stock to Uptown in exchange for a $12,500,000 reduction in the outstanding balance of the December 2020 Royalty Interest
ALIVUS-LIFE-SCIENCES-LIMITED ALIVUS-LIFE-SCIENCES-LIMITED 90% Napo's third-party contract manufacturer, India-based Alivus Life Sciences Limited (f/k/a Glenmark Life Sciences Limited) ('Alivus'), a research-driven, global, integrated pharmaceutical company, is …
ILIAD ILIAD 90% the Company issued 22 shares of Series L Perpetual Preferred Stock (the “Series L Preferred Stock”) to Iliad
INVESTORS INVESTORS 90% the Redemption Shares (as defined hereunder) that may, from time to time, be issued or become issuable to the Investors under the Preferred Stock Purchase Agreements
STREETERVILLE STREETERVILLE 90% the Company issued 99.3822 shares of Series L Preferred Stock to Streeterville
INDENA-S-P-A INDENA-S-P-A 85% Additionally, Napo is establishing a second processing site, which will be operated by Indena S.p.A. ('Indena'), a Milan, Italy-based contract manufacturer dedicated to the identification, developmen…
CHICAGO-VENTURE-PARTNERS-L-P CHICAGO-VENTURE-PARTNERS-L-P 70% The Company received a gain on extinguishment of part of the debts owed to certain affiliates of Chicago Venture Partners, L.P.

Jaguar Health, Inc. Customers

TickerNameConfidenceEvidence
INSTITUTIONAL-INVESTOR INSTITUTIONAL-INVESTOR 92% the shares of Common Stock to be sold and issued by the Company to the Institutional Investor under the ELOC Agreement
WOODWARD WOODWARD 92% Our future revenue stream will substantially come from one customer, Woodward, and will solely be dependent on that certain manufacturing and supply agreement, dated January 12, 2026, by and among Na…
CAH Cardinal Health, Inc. 85% s promise to transfer Mytesi to specialty pharmacies based on specified payment and shipping terms as outlined in the Exclusive Distribution Agreement entered into by the Company and Cardinal Health,…
CAH Cardinal Health, Inc. 85% Reciprocal relationship from CAH graph: Reciprocal relationship from JAGX graph: Reciprocal relationship from CAH graph: Reciprocal relationship from JAGX graph: s promise to transfer Mytesi to speci…

Jaguar Health, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
JAGX-DEBT Debt stack $43.6M 90% Market cache reports total debt of $43.6M.
JAGX-DEBT-10414 Xbrl Convertible 90% xbrl convertible detail from xbrl 2025-12-31.
JAGX-DEBT-10413 Warrants outstanding: 9580 90% xbrl warrant detail from xbrl 2025-12-31.

Jaguar Health, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Jaguar Health, Inc..

Jaguar Health, Inc. Ownership

HolderNameConfidenceEvidence
JAGX-OWNER-UBS-GROUP-AG UBS Group AG 90% 13F overlay lists UBS Group AG as top holder; 12 tracked holders.

Jaguar Health, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
APT Alpha Pro Tech, Ltd. 100.00 2
ARDX Ardelyx, Inc. 100.00 2
MCK McKesson Corporation 100.00 2
GILD Gilead Sciences, Inc. 100.00 2
GRDN Guardian Pharmacy Services, Inc. 100.00 2
CVS CVS Health Corporation 100.00 2
HRMY Harmony Biosciences Holdings, Inc. 100.00 2
MASI Masimo Corporation 100.00 2
MGNX MacroGenics, Inc. 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
EMMA Emmaus Life Sciences, Inc. 100.00 2
NEUP Neuphoria Therapeutics Inc. 100.00 2
CYCN Cyclerion Therapeutics, Inc. 50.00 2
COR Cencora, Inc. 50.00 2
ORANY ORANGE 50.00 2
AMPH Amphastar Pharmaceuticals, Inc. 50.00 2
SUPN Supernus Pharmaceuticals, Inc. 50.00 2
HCSG Healthcare Services Group, Inc. 50.00 2
ADCT ADC Therapeutics SA 50.00 2
VTRS Viatris Inc. 50.00 2